Search

everythinglearnresearchcommunity

for

Search:↓

Early-stage Alopecia Areata was effectively treated in less than six months.

No link between scalp patterns and alopecia severity in children, but more severe cases often had nail abnormalities.

Diphenylcyclopropenone is more effective and has fewer side effects than dinitrochlorobenzene for treating alopecia areata.

A teenager had both alopecia areata and vitiligo, which are rare to occur together.

Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.

No cure exists for alopecia areata, and treatments are personalized.

New hair loss treatments show promise, but more research is needed to confirm their effectiveness.

Both Betasalic ointment and 5% minoxidil are effective and safe for treating Alopecia Areata.

Hair damage shows as fragility, dullness, and discoloration, varies by ethnicity, and is worsened by cosmetic procedures and diseases.

Dermatoscopy is useful for identifying different hair and scalp conditions and can reduce the need for biopsies.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Low iron levels may be linked to some types of hair loss in women.

Some vitamins and minerals like vitamin D and iron can help with certain types of hair loss, but more research is needed for others.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.

The document concludes that understanding and treating hair loss requires recognizing its various types and using appropriate diagnostic tools and treatments.

People with atopic dermatitis are more likely to develop other skin conditions due to shared genetics and immune pathways.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Hair loss in mice starts with immune cells damaging hair roots before it becomes visible.

Chemotherapy can cause hair changes similar to alopecia areata, which might lead to misdiagnosis.

Alopecia areata is linked to thyroid autoimmunity but not type 1 diabetes.

Older age at onset of alopecia areata leads to less severe and shorter episodes, with most patients experiencing significant hair regrowth.

Diagnosing hair loss disorders needs clinical, dermoscopic, and histological differences, and checking menstrual cycle, weight changes, drug therapy, and nail changes.

People with alopecia areata often have higher rates of allergies and autoimmune diseases.

Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.

Diphencyprone treatment increases CD8 lymphocytes in the scalp, which is associated with hair regrowth in alopecia areata patients.

Dupilumab for atopic dermatitis may cause new or worsen existing alopecia areata.

An 8-year-old girl with vitiligo developed extra hair growth on her knee after using tacrolimus ointment.

People with alopecia areata have higher levels of a heart disease marker than those without hair loss.